Screener
Fulgent Genetics, Inc. FLGT Laboratory Services — Finite Lived Intangible Assets Net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Weighted-Average Amortization Period | March 31, 2026 | December 31, 2025 |
|---|---|---|---|
| Purchased patent | 10 Years | 29 | 29 |
| Less: accumulated amortization | (15) | (14) | |
| Purchased patent, net | 14 | 15 | |
| Total | 83,295 | 62,555 | |
| Therapeutic Development | |||
| Customer relationships | 18 Years | 2,300 | 2,300 |
| Less: accumulated amortization | (96) | (64) | |
| Customer relationships, net | 2,204 | 2,236 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s laboratory services — finite lived intangible assets net?
- Fulgent Genetics, Inc. (FLGT) reported laboratory services — finite lived intangible assets net of $83.3M in Q1 2026.
- How has Fulgent Genetics, Inc.'s laboratory services — finite lived intangible assets net changed year-over-year?
- Fulgent Genetics, Inc.'s laboratory services — finite lived intangible assets net increased by 21.7% year-over-year, from $68.42M to $83.3M.
- What does laboratory services — finite lived intangible assets net mean?
- This metric reflects the net book value of the laboratory services segment's finite-lived intangible assets after accounting for accumulated amortization. It represents the remaining unamortized value of these assets, which are expected to contribute to future revenue generation.
Ask your AI about Fulgent Genetics, Inc.'s laboratory services — finite lived intangible assets net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude